A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells

Nature Chemistry

Volumn 9, Issue 9, 2017, Pages 874-881

  Stöhr, Jan ^a,b   Wu, Haifan ^a   Nick, Mimi ^a   Wu, Yibing ^a   Bhate, Manasi ^a   Condello, Carlo ^a,b   Johnson, Noah ^a   Rodgers, Jeffrey ^c   Lemmin, Thomas ^a   Acharya, Srabasti ^a   Becker, Julia ^a   Robinson, Kathleen ^a   Kelly, Mark J S ^a   Gai, Feng ^c   Stubbs, Gerald ^d   Prusiner, Stanley B ^a,b   DeGrado, William F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE FRAGMENT; PROTEIN AGGREGATE; TAU PROTEIN;

BINDING SITE; CELLS; CHEMISTRY; DRUG EFFECT; HEK293 CELL LINE; HUMAN; METABOLISM; MICROTUBULE; PROTEINOSIS;

BINDING SITES; CELLS; HEK293 CELLS; HUMANS; MICROTUBULES; PEPTIDE FRAGMENTS; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS;

EID: 85028330778     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/NCHEM.2754     Document Type: Article

References (38)

1. Prusiner, S. B. A unifying role for prions in neurodegenerative diseases. Science 336, 1511-1513 (2012).
2. Sanders, D. W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271-1288 (2014).
3. Braak, H. & Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16, 271-284 (1995).
4. Clavaguera, F. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. USA 110, 9535-9540 (2013).
5. Boluda, S. et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol. 129, 221-237 (2015).
6. Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5-21 (2016).
7. Morris, M. et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183-1189 (2015).
8. Goedert, M., Falcon, B., Clavaguera, F. & Tolnay, M. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr. Neurol. Neurosci. Rep. 14, 495-491-495-411 (2014).
9. Wischik, C. M. et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA 85, 4884-4888 (1988).
10. Wille, H., Drewes, G., Biernat, J., Mandelkow, E.-M. & Mandelkow, E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J. Cell. Biol. 118, 573-584 (1992).
11. von Bergen, M. et al. Assembly of τ protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK)311)) forming β structure. Proc. Natl Acad. Sci. USA 97, 5129-5134 (2000).
12. Sawaya, M. R. et al. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447, 453-457 (2007).
13. Sievers, S. A. et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475, 96-100 (2011).
14. Daebel, V. et al. β-sheet core of tau paired helical filaments revealed by solid-state NMR. J. Am. Chem. Soc. 134, 13982-13989 (2012).
15. Tomoo, K. et al. Possible role of each repeat structure of the microtubule-binding domain of the tau protein in in vitro aggregation. J. Biochem. 138, 413-423 (2005).
16. Adamcik, J. et al. Microtubule-binding R3 fragment from tau self-assembles into giant multistranded amyloid ribbons. Angew. Chem. Int. Ed. 55, 618-622 (2016).
17. LeVine, H. Thioflavine T interaction with synthetic Alzheimer's disease b-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410 (1993).
18. Goedert, M. et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550-553 (1996).
19. Wilson, D. M. & Binder, L. I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150, 2181-2195 (1997).
20. Woerman, A. L. et al. Propagation of prions causing synucleinopathies in cultured cells. Proc. Natl Acad. Sci. USA 112, E4949-E4958 (2015).
21. Furukawa, Y., Kaneko, K. & Nukina, N. Tau protein assembles into isoform- and disulfide-dependent polymorphic fibrils with distinct structural properties. J. Biol. Chem. 286, 27236-27246 (2011).
22. Soeda, Y. et al. Toxic tau oligomer formation blocked by capping of cysteine residues with 1, 2-dihydroxybenzene groups. Nat. Commun. 6, 10216 (2015).
23. Bhattacharya, K., Rank, K. B., Evans, D. B. & Sharma, S. K. Role of cysteine-291 and cysteine-322 in the polymerization of human tau into Alzheimer-like filaments. Biochem. Biophys. Res. Commun. 285, 20-26 (2001).
24. Barghorn, S. & Mandelkow, E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41, 14885-14896 (2002).
25. Velasco, A. et al. Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans, trans)-1-fluoro-2, 5-bis(3-hydroxycarbonyl-4- hydroxy)styrylbenzene]. FEBS Lett. 582, 901-906 (2008).
26. Harada, R. et al. Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer's disease brain. Mol. Imaging Biol. 16, 19-27 (2014).
27. Astbury, W. T., Dickinson, S. & Bailey, K. CCLXXIX. The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem. J. 29, 2351-2361 (1935).
28. Wille, H. et al. Natural and synthetic prion structure from X-ray fiber diffraction. Proc. Natl Acad. Sci. USA 106, 16990-16995 (2009).
29. Jahn, T. R. et al. The common architecture of cross-beta amyloid. J. Mol. Biol. 395, 717-727 (2010).
30. Wan, W. et al. Degradation of fungal prion HET-s(218-289) induces formation of a generic amyloid fold. Biophys. J. 102, 2339-2344 (2012).
31. Wan, W. et al. Heterogeneous seeding of a prion structure by a generic amyloid form of the fungal prion-forming domain HET-s(218-289). J. Biol. Chem. 288, 29604-29612 (2013).
32. Legname, G. et al. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc. Natl Acad. Sci. USA 103, 19105-19110 (2006).
33. Zhang, Y.-Z., Paterson, Y. & Roder, H. Rapid amide proton exchange rates in peptides and proteins measured by solvent quenching and two-dimensional NMR. Protein Sci. 4, 804-814 (1995).
34. Takegoshi, K., Nakamura, S. & Terao, T. 13C-1H dipolar-driven 13C-13C recoupling without 13C rf irradiation in nuclear magnetic resonance of rotating solids. J. Chem. Phys. 118, 2325-2341 (2003).
35. Wang, Y. & Jardetzky, O. Probability-based protein secondary structure identification using combined NMR chemical-shift data. Protein Sci. 11, 852-861 (2002).
36. Ritter, C. et al. Correlation of structural elements and infectivity of the HET-s prion. Nature 435, 844-848 (2005).
37. Takada, L. T. & Geschwind, M. D. Prion diseases. Semin. Neurol. 33, 348-356 (2013).
38. Wan, W., Stöhr, J., Kendall, A. & Stubbs, G. Truncated forms of the prion protein PrP demonstrate the need for complexity in prion structure. Prion 9, 333-338 (2015).